Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
GENB Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
36.48%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Generate Biomedicines, Inc.
Market Cap
$1.78B
Return on Equity (ROE)
N/A
TTM Avg
36.48%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.78B
Return on Equity (ROE)
-54.96%
TTM Avg
-60.50%
3Y Avg
-51.30%
5Y Avg
-42.73%
Market Cap
$1.76B
Return on Equity (ROE)
15.35%
TTM Avg
-64.31%
3Y Avg
-71.44%
5Y Avg
-70.74%
Market Cap
$1.83B
Return on Equity (ROE)
4.88%
TTM Avg
4.47%
3Y Avg
6.79%
5Y Avg
5.89%
Market Cap
$1.71B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$1.87B
Return on Equity (ROE)
-40.09%
TTM Avg
4.56%
3Y Avg
-13.84%
5Y Avg
-2.18%
Market Cap
$1.89B
Return on Equity (ROE)
12.01%
TTM Avg
-4.52%
3Y Avg
-16.89%
5Y Avg
-11.36%
Market Cap
$1.65B
Return on Equity (ROE)
17.72%
TTM Avg
5.08%
3Y Avg
0.03%
5Y Avg
-3.88%
Market Cap
$1.65B
Return on Equity (ROE)
N/A
TTM Avg
-1058.20%
3Y Avg
-465.87%
5Y Avg
-348.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.78B | N/A | 36.48% | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.78B | -54.96% | -60.50% | -51.30% | -42.73% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.76B | 15.35% | -64.31% | -71.44% | -70.74% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 4.88% | 4.47% | 6.79% | 5.89% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -40.41% | -45.75% | -30.11% | -18.95% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | -40.09% | 4.56% | -13.84% | -2.18% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 12.01% | -4.52% | -16.89% | -11.36% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 17.72% | 5.08% | 0.03% | -3.88% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | N/A | -1058.20% | -465.87% | -348.95% |
| Absci Corporation (ABSI)vs › | $1.95B | -49.19% | -59.18% | -54.84% | -44.72% |
ROE
N/A
ROA
-61.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 32.98% |
| 2024-12-31 | 39.99% |
